Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -2.27%37 PB Ratio is 1.51 as of Jul. 24, 2026, which is 34% above its 10-year median of 1.13. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 921 Drug Manufacturers companies, Techno Drugs ranks better than 59.39% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-24), Techno Drugs's share price is BDT47.30. Techno Drugs's Book Value per Share for the quarter that ended in Mar. 2026 was BDT31.38. Hence, Techno Drugs's PB Ratio of today is 1.51.
Warning Sign:
Techno Drugs Ltd stock PB Ratio (=1.49) is close to 1-year high of 1.49.
The historical rank and industry rank for Techno Drugs's PB Ratio or its related term are showing as below:
DHA:TECHNODRUG'
s PB Ratio Range Over the Past 10 Years
Min: 0.83 Med: 1.13 Max: 2.66
Current: 1.51
During the past 2 years, Techno Drugs's highest PB Ratio was 2.66. The lowest was 0.83. And the median was 1.13.
DHA:TECHNODRUG's PB Ratio is ranked better than 59.39% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.87
vs DHA:TECHNODRUG: 1.51
During the past 12 months, Techno Drugs's average Book Value Per Share Growth Rate was 3.80% per year.
Back to Basics: PB Ratio
Techno Drugs (DHA:TECHNODRUG) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Techno Drugs PB Ratio Related Terms
Techno Drugs PB Ratio Historical Data
* Premium members only.
The historical data trend for Techno Drugs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Techno Drugs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Techno Drugs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Techno Drugs (DHA:TECHNODRUG) has a PB Ratio of 1.51 as of Jul. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Techno Drugs and its competitors. This is 34% above median its historical median of 1.13. Over the past decade, Techno Drugs' PB Ratio has ranged from 0.83 to 2.66. According to the industry distribution chart, Techno Drugs ranks #374 out of 921 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Techno Drugs' PB Ratio too high?
Techno Drugs' current PB Ratio of 1.51 is 34% above median its 10-year median of 1.13. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 2.66. The Drug Manufacturers industry median PB Ratio is 1.87. Techno Drugs' value of 1.51 is 19.3% below this industry median. Based on the distribution chart, Techno Drugs ranks #374 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #374 out of 921 companies for PB Ratio. This puts Techno Drugs in the upper half of its industry. The industry median PB Ratio is 1.87. Techno Drugs' value of 1.51 is 19.3% below this benchmark. Historically, Techno Drugs' own PB Ratio has ranged from 0.83 to 2.66 over the past decade. While the company's 10-year median is 1.13 vs. the industry median of 1.87, Techno Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.87, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Techno Drugs's current PB Ratio of 1.51 is 19.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current PB Ratio is 1.51, which is 34% above median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current PB Ratio of 1.51. The current PB Ratio is 1.51, which is 34% above median its 10-year median of 1.13 and 19.3% below the Drug Manufacturers industry median of 1.87. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current PB Ratio is 1.51 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
